CONSTELLATION PHARMACEUTICALS INC
CONSTELLATION PHARMACEUTICALS INC (CNST): 6 pipeline candidates · ~28 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
28.2 months
D/E 0.07 · 0% dilution
Lead: Phase 1/Phase 2
6 candidates
N/A
N/A
A transparent, data-derived signal for CONSTELLATION PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$117.2M
Quarterly Burn
$39.7M
Runway
28.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| abiraterone | Phase 1/Phase 2 |
| cpi-0209 | Phase 1/Phase 2 |
| cpi-0610 | Phase 2 |
| cpi-1205 | Phase 1/Phase 2 |
| cpi-482 | Preclinical |
| pelabresib | Phase 1 |
Frequently asked questions
How many drug candidates are in CONSTELLATION PHARMACEUTICALS INC's pipeline?
CONSTELLATION PHARMACEUTICALS INC (CNST) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CONSTELLATION PHARMACEUTICALS INC's lead drug candidate?
CONSTELLATION PHARMACEUTICALS INC's most advanced tracked candidate is abiraterone (Phase 1/Phase 2) for Metastatic Castration Resistant Prostate Cancer (mCRPC).
What is CONSTELLATION PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CONSTELLATION PHARMACEUTICALS INC has approximately 28.2 months of cash runway.
Who is the CEO of CONSTELLATION PHARMACEUTICALS INC?
Jigar Raythatha is the chief executive officer of CONSTELLATION PHARMACEUTICALS INC (CNST).
Get the full picture on CONSTELLATION PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.